266 related articles for article (PubMed ID: 19132343)
1. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.
Mouly S; Meune C; Bergmann JF
Intensive Care Med; 2009 Mar; 35(3):417-29. PubMed ID: 19132343
[TBL] [Abstract][Full Text] [Related]
2. CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides.
Sergent T; Dupont I; Jassogne C; Ribonnet L; van der Heiden E; Scippo ML; Muller M; McAlister D; Pussemier L; Larondelle Y; Schneider YJ
Toxicol Lett; 2009 Feb; 184(3):159-68. PubMed ID: 19070657
[TBL] [Abstract][Full Text] [Related]
3. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions.
Marathe PH; Rodrigues AD
Curr Drug Metab; 2006 Oct; 7(7):687-704. PubMed ID: 17073574
[TBL] [Abstract][Full Text] [Related]
4. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc: in vitro assessment of drug-drug interaction potential.
Hyland R; Dickins M; Collins C; Jones H; Jones B
Br J Clin Pharmacol; 2008 Oct; 66(4):498-507. PubMed ID: 18647303
[TBL] [Abstract][Full Text] [Related]
6. Drugs as CYP3A probes, inducers, and inhibitors.
Liu YT; Hao HP; Liu CX; Wang GJ; Xie HG
Drug Metab Rev; 2007; 39(4):699-721. PubMed ID: 18058330
[TBL] [Abstract][Full Text] [Related]
7. Drug metabolism and drug interactions: application and clinical value of in vitro models.
Venkatakrishnan K; von Moltke LL; Obach RS; Greenblatt DJ
Curr Drug Metab; 2003 Oct; 4(5):423-59. PubMed ID: 14529374
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
9. MDR- and CYP3A4-mediated drug-drug interactions.
Pal D; Mitra AK
J Neuroimmune Pharmacol; 2006 Sep; 1(3):323-39. PubMed ID: 18040809
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
11. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
12. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
[TBL] [Abstract][Full Text] [Related]
14. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
Weiss J; Sawa E; Riedel KD; Haefeli WE; Mikus G
Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):275-82. PubMed ID: 18516595
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
17. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
18. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
19. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
20. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
